Skip to content

Science

Neurotoxin biology,engineered for what's next.

Botulinum neurotoxins are among the most precise biological tools in medicine — and not all of them are biologically identical. Object Pharma is exploring how differentiated neurotoxin biology could open new therapeutic possibilities, beginning with mental health.

The neuromuscular junction

01

Targeted uptake

Botulinum neurotoxins bind with high specificity to presynaptic nerve terminals and are internalized into the neuron.

02

Intracellular action

The neurotoxin light chain acts on proteins of the vesicle-release machinery inside the nerve terminal.

03

Modulated signaling

Neurotransmitter release at the junction is reduced, altering the signal between nerve and muscle.

04

Recovery

Signaling recovers over time as nerve terminals restore release function — a profile that differs by serotype.

Serotype landscape

Botulinum neurotoxin serotype A

The most extensively characterized serotype, and the basis of the first approved therapeutic neurotoxin products.

Research-use material — not a clinical product

Serotype biology

Botulinum neurotoxins comprise multiple serotypes — A through G — with distinct receptors, substrates and kinetic profiles. This natural diversity is a foundation of Object Pharma's platform thinking.

Differentiated kinetics

Biological differences between neurotoxins may translate into different profiles of onset and duration. Object Pharma is investigating how these differences could be matched to different therapeutic questions.

Statements on this page describe class-level biology and published external research. They do not constitute clinical evidence for OP01 or any Object Pharma candidate.